SAN LUIS OBISPO, Calif. - Oct. 15, 2002 - FzioMed, Inc., a leading developer of absorbable biosurgery products, presented findings from its pre-clinical research to develop an anti-adhesion product for use in preventing post-surgical adhesions in abdominal/pelvic surgery. The presentation was made at the 58th Annual Meeting of the American Society for Reproductive Medicine held October 14 through October 16, 2002 in Seattle, Washington.

Dr. Richard Berg, Vice President of Research and Development for FzioMed, reported that the novel site-specific anti-adhesion gel, derived from FzioMed's Oxiplex® technology, reduced the area for re-adhesions by 89% in rabbits undergoing surgery to lyse adhesions. The Oxiplex® gel is a bioabsorbable adhesion barrier being developed to reduce post-surgical adhesions, a leading complication of many surgical procedures.

FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company's patented Oxiplex® platform technology. Oxiplex® is an innovative polymer that is formulated for a variety of medical indications and markets. Products in development include those for the prevention of post-surgical adhesions, drug delivery and hemostasis. FzioMed products are at various stages of clinical and pre-clinical development, and are directed towards high growth markets in the rapidly growing field of biosurgery.

Oxiplex® is a registered trademark of FzioMed, Inc.

Back to News Articles